Aims: Cardiac resynchronization therapy (CRT) is indicated in patients with heart failure and bundle branch block. It is less clear whether this includes patients with pre-existing right ventricular pacemaker/defibrillator systems, particularly with respect to implantation success and clinical benefit.
Methods And Results: In consecutive patients scheduled for CRT, we prospectively compared implantation success, procedural parameters, and clinical response in 'de novo' vs. upgrade procedures of previously implanted right ventricular systems. CRT implantation was attempted in 79 consecutive patients (64 +/- 11 years, 63 male, 38 ischaemic, 41 non-ischaemic cardiomyopathy). De novo implantation was performed in 61 patients, upgrade procedures in 18 patients. Implant success (92 vs. 94%, P = 1.00), procedure duration (153 +/- 43 vs. 164 +/- 65 min, P = 0.51), fluoroscopy time (25 +/- 18 vs. 32 +/- 22 min, P = 0.18) or dose (40 +/- 31 vs. 52 +/- 49 Gy/cm(2), P = 0.35), and response rate (66 vs. 59%, P = 0.5) were comparable for both groups.
Conclusion: Procedural aspects, implantation success, and clinical response to CRT were comparable for patients undergoing de-novo vs. upgrade procedures. Accordingly, patient selection for upgrading should be the same as for new CRT implantation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/europace/eum259 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Magnetic resonance angiography in diagnostic long-term follow-up of primary patency of the MOTIV drug-eluting bioresorbable vascular scaffold in the region below the knee: 5 years of experience.
PLoS One
January 2025
Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, Austria.
Purpose: Treatment of peripheral artery disease (PAD) in the region below the knee (BTK) is dissatisfying as failure of treated target lesions (TLF) is frequent and diagnostic imaging is often challenging. In the BTK-region metallic drug-eluting stents (mDES) yielded best results concerning primary patency (PP), but also annihilate signal in magnetic resonance angiography (MR-A). A recently introduced non-metallic drug eluting bioresorbable Tyrocore® vascular scaffold (deBVS), that offers an option for re-treatment of lesions due to its full degradation within 3-4 years after placement, was investigated with respect to its compatibility with MR-A to unimpededly depict previously treated target lesions.
View Article and Find Full Text PDFHow Often Is Rifampin Therapy Initiated and Completed in Patients With Periprosthetic Joint Infections?
Clin Orthop Relat Res
January 2025
Department of Medicine, Duke University, Durham, NC, USA.
Background: Rifampin therapy is indicated for the treatment of staphylococcal periprosthetic joint infection (PJI) in patients who have undergone debridement, antibiotics, and implant retention (DAIR) or one-stage revision as per the Infectious Diseases Society of America (IDSA) guideline. Given the well-established effectiveness of rifampin as adjunctive therapy in staphylococcal PJI, it is crucial to evaluate its utilization in practice and identify factors that contribute to its underuse or incomplete administration, as these deviations may undermine treatment efficacy and patient outcomes.
Questions/purposes: Among patients who met clear indications for rifampin use having undergone DAIR or one-stage revision for staphylococcal PJI, (1) what proportion of patients did not receive it? (2) What proportion of patients started it but did not complete the planned course? (3) Where documented in the medical record, what were the common reasons for not using it or prematurely discontinuing it, and in what percentage of the patients' charts was no reason given? (4) What proportion of patients were taking a medication that put them at risk for a drug-drug interaction (DDI)?
Methods: Using an institutional database, patients who underwent DAIR or revision arthroplasty for PJI from January 2013 to April 2023 were identified (n = 935).
A surgical orthotopic xenograft approach with immune response for colorectal cancer research.
Animal Model Exp Med
January 2025
Cancer Institute, School of Medicine, Jianghan University, Wuhan, China.
The high morbidity and mortality of colorectal cancer (CRC) is a major challenge in clinical practice. Although a series of alternative research models of CRC have been developed, appropriate orthotopic animal models that reproduce the specific clinical response as well as pathophysiological immune features of CRC are still lacking. In the current study, we constructed a CRC orthotopic xenograft model by implanting the tumor tubes at the colorectum of mice and monitored the model development using bioluminescence imaging.
View Article and Find Full Text PDFPermanent Left Bundle Branch Area DF-4 Defibrillator Lead Implantation-Feasibility, Procedural Caveats, Safety, and Follow-Up.
J Cardiovasc Electrophysiol
January 2025
Department of Cardiac Electrophysiology and Pacing, Arrhythmia Heart Failure Academy, The Madras Medical Mission, Chennai, Tamil Nadu, India.
Introduction: Permanent implantation of a DF-4 implantable cardiac defibrillator (ICD) lead in the left bundle branch area (LBBA-ICD) is the next paradigm in amalgamating cardiac resynchronization therapy (CRT) and defibrillation. We systematically investigated feasibility/success rate, procedural caveats, and complications associated with a permanent DF-4 LBBA ICD implant and pertinent data at short-term follow-up.
Methods: We prospectively attempted implantation of 7 Fr Durata (Abbott, Chicago, IL, USA) single coil DF-4 ICD lead at the LBBA using a fixed-curve non-deflectable CPS locator delivery sheath.
One tube for all: 1-year outcomes after transition to Paul glaucoma implant at a tertiary centre.
Acta Ophthalmol
January 2025
Department of Ophthalmology, Aarhus University Hospital, Aarhus, Denmark.
Purpose: To evaluate the intraocular pressure (IOP) lowering effect and success rate of Paul glaucoma implant (PGI) in refractory glaucoma after changing practice pattern from Ahmed and Baerveldt tubes to PGI.
Methods: A prospective observational study of the first 50 consecutive PGI surgeries at a single Danish tertiary centre from January 2022 to October 2023. Primary endpoints were IOP and success rates after 12 months.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!